Kiora Pharmaceuticals Presents Plans for Global Phase 3 Trial of KIO-401 in Retinal Artery Occlusion

Bitget2026/10/29 11:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Kiora Pharmaceuticals added KIO-401, a Phase 3-ready oral calpain inhibitor for central retinal artery occlusion, securing rights outside Asia from Senju Pharmaceutical.
A planned global Phase 3 trial will enroll approximately 144 patients across up to 50 sites.
Japan Phase 3 visual acuity results showed p=0.0949 overall versus p=0.0195 in patients with baseline vision worse than 20/400.
Planned NAION development includes a Phase 2b trial enrolling approximately 272 patients, with label expansion targeted for 2033.
KIO-301 remains in an actively enrolling Phase 2 trial for advanced retinitis pigmentosa.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kiora Pharmaceuticals Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Kiora Pharmaceuticals Presents Plans for Global Phase 3 Trial of KIO-401 in Retinal Artery Occlusion

You may also like

Crypto prices